Heart failure & cardiomyopathies
First Italian multicentre registry for Mechanically Assisted Circulatory Support (ITAMACS) report: 12-year experience of over 1000 durable left ventricular assist device (LVAD) patients
Authors' conclusion
ITAMACS is the first national registry reporting real-world outcomes of durable LVAD therapy in Italy.
Study context
- Population
- Patients undergoing durable intracorporeal LVAD implantation for advanced HF in Italy, January 2010–December 2021
- Participants
- 1,061 patients12 centres
- Outcome
- Overall survival
Methodological detailsnational registry
- National registry
Main finding
As reported in the abstract
Overall survival at 1 year
73%
Overall survival at 3 years
54%
Overall survival at 5 years
42%
Observational data: associations, not effects.
Further findings
Independent predictors of long-term mortality (multivariable Cox)
| HR (95% CI) | ||
|---|---|---|
| Older ageHigher mortality | 1.02 (1.01–1.04) | |
| Redo surgeryHigher mortality | 1.25 (1.02–1.55) | |
| INTERMACS class >1Protective | 0.66 (0.50–0.87) | |
| BTT indicationProtective | 0.63 (0.48–0.83) | |
| 0.512Hazard ratio (log scale) |
Patient characteristics
- Bridge-to-transplantation (BTT) indication
- 40.5%
- Destination therapy (DT) indication
- 38.8%
- INTERMACS class 1
- 14.8%
- Minimally invasive implantation
- 16.3%
Original publication
First Italian multicentre registry for Mechanically Assisted Circulatory Support (ITAMACS) report: 12-year experience of over 1000 durable LVAD patients. Eur J Heart Fail. Published 13 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →